SCIENTISTS at the Ineos Oxford Institute for antimicrobial research have been given £1 million to help speed up the development of a new class of antibiotics. Pathways to Antimicrobial Clinical Efficacy made the donation after the scientists discovered a new small class of inhibitors which could treat many drug-resistant superbugs.
Professor Chris Schofield, Director of Chemistry, said the institute’s fantastic team of biochemists, microbiologists and chemists were ‘massively excited’ to be working with the PACE team.
PACE was founded in 2023 to help the world’s best innovators speed up their research into the growing resistance to antibiotics.
The IOI’s project is among the first to receive funding.
“We look forward to supporting them to move their project closer to the clinic, which would have a huge impact on patients’ lives,” said Dr Beverley Isherwood, PACE Programme Director. In addition to the funding, the institute will be offered R&D advice from a global network of experts, access to a microbiology platform and medicinal chemistry expertise.
Antibiotic resistance is seen as a silent killer that threatens the foundation of modern medicine. Scientists have been warning for years that medicine will be taken back to the dark ages if new drugs are not found to replace existing antibiotics that have lost their efficacy.
They fear common infections, which have been successfully treated with antibiotics for decades, could become killers once again Illnesses, which have evolved to become difficult or impossible to treat with antibiotics, already kill about 1.5 million people a year. But more than 10 million could die every year by 2050.
Ever since the discovery of penicillin in 1928, β-lactam antibiotics have been a mainstay of treatment for bacterial infections. These antibiotics have a β-lactam ring that stops bacteria from growing and developing. But bacteria have evolved by producing β-lactamase, an enzyme capable of disabling β-lactam antibiotics, rendering them useless against such common illnesses as urinary tract infections.
“Hospital stays for patients with antibioticresistant infections average around 13 days, causing an additional 8 million hospital days annually,” said Professor Schofield.
Scientists at the IOI, though, have developed small molecule transpeptidase inhibitors that do not contain a β-lactam unit and are not affected by many β-lactamases produced by bacteria.
These inhibitors also perform well against a broad spectrum of bacteria that causes such infections as pneumonia, gastroenteritis and meningitis.
FLIES
Flies in Nigerian hospitals carry bacteria resistant to clinically important antibiotics, including last-resort antibiotics.
MICROPLASTICS
The presence of microplastics in the environment increased the spread of antibiotic resistance by up to 200 times.
LIVESTOCK
97% of human campylobacter infections, which causes diarrhoea, in the US between 2009 and 2019 came from livestock reservoirs on contaminated meat.
WILD BIRDS
Wild birds, such as ducks and crows that live in cities, are likely to carry bacteria with anti-microbial resistance.
DISINFECTANT
Prolonged exposure to antibacterial disinfectant can increase antibiotic resistance.
COLISTIN
The use of colistin in animal feed – to prevent infections and promote growth – is increasing anti-microbial resistance among humans.